[go: up one dir, main page]

FR2967581B1 - Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques - Google Patents

Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques

Info

Publication number
FR2967581B1
FR2967581B1 FR1059561A FR1059561A FR2967581B1 FR 2967581 B1 FR2967581 B1 FR 2967581B1 FR 1059561 A FR1059561 A FR 1059561A FR 1059561 A FR1059561 A FR 1059561A FR 2967581 B1 FR2967581 B1 FR 2967581B1
Authority
FR
France
Prior art keywords
polymeric
preparation
active ingredients
intermediates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1059561A
Other languages
English (en)
Other versions
FR2967581A1 (fr
Inventor
Abderrhamane Amgoune
Didier Bazile
Fethi Bensaid
Didier Bourissou
Eric Didier
Stephanie Greco
Harivardhan Reddy Lakkireddy
Serge Sable
Michel Veillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Centre National de la Recherche Scientifique CNRS
Universite de Toulouse
Original Assignee
Centre National de la Recherche Scientifique CNRS
Sanofi Aventis France
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1059561A priority Critical patent/FR2967581B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Sanofi Aventis France, Universite Toulouse III Paul Sabatier filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/EP2011/070441 priority patent/WO2012066117A1/fr
Priority to EP11784668.3A priority patent/EP2640422B1/fr
Priority to RS20170450A priority patent/RS56021B1/sr
Priority to US13/877,757 priority patent/US9278137B2/en
Priority to PL11784668T priority patent/PL2640422T3/pl
Priority to SI201131184T priority patent/SI2640422T1/sl
Priority to ES11784668.3T priority patent/ES2625173T3/es
Priority to HRP20170691TT priority patent/HRP20170691T1/hr
Priority to TW100142380A priority patent/TW201302225A/zh
Priority to UY0001033741A priority patent/UY33741A/es
Priority to JP2013539283A priority patent/JP6013354B2/ja
Priority to HUE11784668A priority patent/HUE032590T2/en
Priority to PT117846683T priority patent/PT2640422T/pt
Priority to ARP110104306A priority patent/AR084728A1/es
Priority to LTEP11784668.3T priority patent/LT2640422T/lt
Priority to DK11784668.3T priority patent/DK2640422T3/en
Publication of FR2967581A1 publication Critical patent/FR2967581A1/fr
Application granted granted Critical
Publication of FR2967581B1 publication Critical patent/FR2967581B1/fr
Priority to JP2016080318A priority patent/JP6165920B2/ja
Priority to CY20171100570T priority patent/CY1119115T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
FR1059561A 2010-11-19 2010-11-19 Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques Active FR2967581B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR1059561A FR2967581B1 (fr) 2010-11-19 2010-11-19 Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
JP2013539283A JP6013354B2 (ja) 2010-11-19 2011-11-18 活性成分のポリマーコンジュゲート、その製造方法及びそのポリマー中間体
RS20170450A RS56021B1 (sr) 2010-11-19 2011-11-18 Polimerni konjugati aktivnih principa, procesi za njihovu pripremu i njihovi polimerni interminedijari
US13/877,757 US9278137B2 (en) 2010-11-19 2011-11-18 Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates
PL11784668T PL2640422T3 (pl) 2010-11-19 2011-11-18 Polimerowe koniugaty aktywnych zasad, sposób ich otrzymywania i ich polimerowe produkty pośrednie
SI201131184T SI2640422T1 (sl) 2010-11-19 2011-11-18 Polimerni konjugati aktivnih učinkovin, postopek njihove priprave in njihove polimerne vmesne spojine
ES11784668.3T ES2625173T3 (es) 2010-11-19 2011-11-18 Conjugados poliméricos de principios activos, su procedimiento de preparación y sus intermedios poliméricos
PT117846683T PT2640422T (pt) 2010-11-19 2011-11-18 Conjugados poliméricos de princípios ativos, seu processo de preparação e seus intermediários poliméricos
EP11784668.3A EP2640422B1 (fr) 2010-11-19 2011-11-18 Conjugués polymères de principes actifs, leur procédé de préparation et leurs intermédiaires polymères
UY0001033741A UY33741A (es) 2010-11-19 2011-11-18 Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos
PCT/EP2011/070441 WO2012066117A1 (fr) 2010-11-19 2011-11-18 Conjugués polymères de principes actifs, leur procédé de préparation et leurs intermédiaires polymères
TW100142380A TW201302225A (zh) 2010-11-19 2011-11-18 活性成份之聚合共軛物，其製備方法及其聚合中間物
HRP20170691TT HRP20170691T1 (hr) 2010-11-19 2011-11-18 Polimerni konjugati djelatnih tvari, njihov postupak dobivanja i njihovi polimerni intermedijeri
ARP110104306A AR084728A1 (es) 2010-11-19 2011-11-18 Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos
LTEP11784668.3T LT2640422T (lt) 2010-11-19 2011-11-18 Veikliųjų medžiagų polimeriniai konjugatai, jų gamybos būdas ir jų polimeriniai tarpiniai junginiai
DK11784668.3T DK2640422T3 (en) 2010-11-19 2011-11-18 POLYMER CONJUGATES OF ACTIVE INGREDIENTS, METHOD OF MANUFACTURING THEREOF AND THEIR POLYMER INTERMEDIATES
HUE11784668A HUE032590T2 (en) 2010-11-19 2011-11-18 Polymer conjugates of active substances, processes for their preparation, and intermediates of polymers
JP2016080318A JP6165920B2 (ja) 2010-11-19 2016-04-13 活性成分のポリマーコンジュゲート、その製造方法及びそのポリマー中間体
CY20171100570T CY1119115T1 (el) 2010-11-19 2017-05-31 Πολυμερικα συζευγματα δραστικων αρχων, η διαδικασια παρασκευης τους και οι πολυμερικες ενδιαμεσες ενωσεις τους

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059561A FR2967581B1 (fr) 2010-11-19 2010-11-19 Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques

Publications (2)

Publication Number Publication Date
FR2967581A1 FR2967581A1 (fr) 2012-05-25
FR2967581B1 true FR2967581B1 (fr) 2012-12-28

Family

ID=43654132

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1059561A Active FR2967581B1 (fr) 2010-11-19 2010-11-19 Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques

Country Status (18)

Country Link
US (1) US9278137B2 (fr)
EP (1) EP2640422B1 (fr)
JP (2) JP6013354B2 (fr)
AR (1) AR084728A1 (fr)
CY (1) CY1119115T1 (fr)
DK (1) DK2640422T3 (fr)
ES (1) ES2625173T3 (fr)
FR (1) FR2967581B1 (fr)
HR (1) HRP20170691T1 (fr)
HU (1) HUE032590T2 (fr)
LT (1) LT2640422T (fr)
PL (1) PL2640422T3 (fr)
PT (1) PT2640422T (fr)
RS (1) RS56021B1 (fr)
SI (1) SI2640422T1 (fr)
TW (1) TW201302225A (fr)
UY (1) UY33741A (fr)
WO (1) WO2012066117A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015422A1 (fr) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Nanoparticules à base de cellulose pour administration de médicament
SG10201705514WA (en) * 2012-12-28 2017-08-30 Tarveda Therapeutics Inc Targeted conjugates encapsulated in particles and formulations thereof
SMT202000162T1 (it) 2013-09-16 2020-05-08 Astrazeneca Ab Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse
WO2017147240A1 (fr) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Conjugués et particules ciblant hsp90 et leurs formulations
WO2020014750A1 (fr) * 2018-07-19 2020-01-23 Starpharma Pty Ltd Dendrimère thérapeutique
CN110974972B (zh) * 2019-12-03 2023-01-20 沈阳药科大学 难溶性药物的弱酸性衍生物及其脂质体制剂
CN113933441A (zh) * 2021-09-30 2022-01-14 无锡紫杉药业有限公司 一种卡巴他赛及其中间体的测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
CN101701068B (zh) * 2009-10-30 2011-09-21 北京化工大学 一种pH响应性的Y型药物输送材料及其制备方法
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN103408710B (zh) * 2013-06-19 2015-12-23 北京化工大学 一种生物可降解及糖响应性的y型高分子药物输送材料及制备

Also Published As

Publication number Publication date
PT2640422T (pt) 2017-05-23
UY33741A (es) 2012-03-30
TW201302225A (zh) 2013-01-16
LT2640422T (lt) 2017-06-26
FR2967581A1 (fr) 2012-05-25
JP6165920B2 (ja) 2017-07-19
JP2013542972A (ja) 2013-11-28
PL2640422T3 (pl) 2017-09-29
ES2625173T3 (es) 2017-07-18
DK2640422T3 (en) 2017-05-22
HUE032590T2 (en) 2017-10-30
CY1119115T1 (el) 2018-02-14
SI2640422T1 (sl) 2017-10-30
AR084728A1 (es) 2013-06-05
US20130243719A1 (en) 2013-09-19
RS56021B1 (sr) 2017-09-29
WO2012066117A1 (fr) 2012-05-24
HRP20170691T1 (hr) 2018-05-18
JP2016172858A (ja) 2016-09-29
JP6013354B2 (ja) 2016-10-25
EP2640422B1 (fr) 2017-03-01
EP2640422A1 (fr) 2013-09-25
US9278137B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
FR19C1040I2 (fr) Administration par voie respiratoire de principes actifs
CO6811868A2 (es) Combinaciones de principios activos
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
FR2962437B1 (fr) Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
FR2986002B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HRP20150029T1 (xx) Farmaceutski pripravak za lijeäśenje metaboliäśkog sindroma
EP2665733A4 (fr) Préparation de réseaux métal- triazolate
PT2683708T (pt) Formas sólidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona, e suas composições e usos farmacêuticos
BR112012023355A2 (pt) composto, composição farmacêutica e método de ruptura da interação nek2/hec1
EP2799540A4 (fr) Arginase humaine et arginase humaine pégylée, et leur application
FR2974576B1 (fr) Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
FR2967581B1 (fr) Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
FR2949465B1 (fr) Derives chromones, leur procede de preparation et leurs applications therapeutiques
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BR112013017267A2 (pt) formulação de lipossomas, suspensão e composição farmacêutica
LT2665464T (lt) Fiziologiškai aktyvių medžiagų nešiklis, skirtas vartoti per burnos gleivinę, ypač po liežuviu
FR2966150B1 (fr) Procede de preparation de la 2-hydroxybutyrolactone
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
FR2973037B1 (fr) Adhesifs structuraux, procede pour leur preparation, et leur application
SMT201600243B (it) Composizioni farmaceutiche comprendenti anakinra senza citrato
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
BR112013033052A2 (pt) formulações de entrega de fármaco

Legal Events

Date Code Title Description
CA Change of address

Effective date: 20120620

CD Change of name or company name

Owner name: UNIVERSITE PAUL SABATIER TOULOUSE III, FR

Effective date: 20120620

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20120620

Owner name: SANOFI, FR

Effective date: 20120620

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8